PE20171340A1 - PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES - Google Patents

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES

Info

Publication number
PE20171340A1
PE20171340A1 PE2017001147A PE2017001147A PE20171340A1 PE 20171340 A1 PE20171340 A1 PE 20171340A1 PE 2017001147 A PE2017001147 A PE 2017001147A PE 2017001147 A PE2017001147 A PE 2017001147A PE 20171340 A1 PE20171340 A1 PE 20171340A1
Authority
PE
Peru
Prior art keywords
treatment
gastrointestinal diseases
pharmaceutical composition
bismuth
composition
Prior art date
Application number
PE2017001147A
Other languages
Spanish (es)
Inventor
Young Ho Jo
Jun Woo Lee
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171340(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of PE20171340A1 publication Critical patent/PE20171340A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se refiere a una composicion que comprende: a) 50 mg a 300 mg de ranitidina; b) 240 mg a 1200 mg de sucralfato de bismuto; y c) 80 mg a 400 mg de subcitrato de bismuto. Dicha formulacion es estable y aumenta la biodisponibilidad biologica de los farmacos, siendo util en el tratamiento de de enfermedades gastrointestinalesIt refers to a composition comprising: a) 50 mg to 300 mg of ranitidine; b) 240 mg to 1200 mg of bismuth sucralfate; and c) 80 mg to 400 mg of bismuth subcitrate. Said formulation is stable and increases the biological bioavailability of drugs, being useful in the treatment of gastrointestinal diseases.

PE2017001147A 2015-01-30 2016-01-28 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES PE20171340A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (en) 2015-01-30 2015-10-22 A pharmaceutical composition for treating gastrointestinal diseases

Publications (1)

Publication Number Publication Date
PE20171340A1 true PE20171340A1 (en) 2017-09-13

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001147A PE20171340A1 (en) 2015-01-30 2016-01-28 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES

Country Status (19)

Country Link
EP (1) EP3250199A4 (en)
JP (1) JP6419347B2 (en)
KR (2) KR101583452B1 (en)
CN (1) CN107205947B (en)
AR (1) AR105413A1 (en)
CL (1) CL2017001680A1 (en)
CO (1) CO2017006222A2 (en)
EA (1) EA032385B9 (en)
EC (1) ECSP17038599A (en)
GE (1) GEP20196941B (en)
MA (1) MA41432A (en)
MX (1) MX2017007567A (en)
MY (1) MY195824A (en)
PE (1) PE20171340A1 (en)
PH (1) PH12017550051A1 (en)
SA (1) SA517382016B1 (en)
TW (1) TWI635859B (en)
UA (1) UA116517C2 (en)
WO (1) WO2016122226A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (en) 2017-10-11 2019-09-24 (주)휴럼 Litsenolide used as an active ingredient for gastrointestinal disease, and A composition comprising the same as an active ingredient
JP2021518422A (en) * 2018-04-13 2021-08-02 サムヤン バイオファーマシューティカルズ コーポレイションＳａｍｙａｎｇ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ Pharmaceutical composition containing lenalidomide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3874917T2 (en) * 1987-03-09 1993-03-04 Procter & Gamble COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF STOMACH.
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (en) * 1992-01-22 1997-04-23 주식회사 대웅제약 A pharmaceutical composition for treating gastrointestinal disorders
KR100264547B1 (en) * 1994-04-26 2000-12-01 나가야마 오사무 Molten granulated sucralfate preparation and process for producing the same
JPH0879097A (en) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd Portable radio equipment
KR970006083A (en) 1995-07-06 1997-02-19 한승준 Installation structure of wire fixing device of automobile cowl
WO1999010000A1 (en) * 1997-08-25 1999-03-04 The Procter & Gamble Company Combined preparations for treating upper gastrointestinal tract distress
AU4655199A (en) 1999-06-21 2001-01-09 Dae Woong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (en) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk Compounding agent for treating/preventing gastritis
WO2010001930A1 (en) * 2008-07-01 2010-01-07 ライオン株式会社 Solid preparation for internal application
KR20110105223A (en) * 2010-03-18 2011-09-26 일양약품주식회사 Oral pharmaceutical composition for preventing or treating a gastroenteric disease comprising ilaprazole and a mixture of sucralfate and bismuth agents
KR20140072673A (en) * 2012-12-05 2014-06-13 (주)한국파비스제약 Oral tablet for treatment of gastrointestinal disease

Also Published As

Publication number Publication date
EA201791458A1 (en) 2017-11-30
GEP20196941B (en) 2019-01-10
MA41432A (en) 2017-12-05
TWI635859B (en) 2018-09-21
CN107205947B (en) 2020-05-22
SA517382016B1 (en) 2021-03-18
KR20160094268A (en) 2016-08-09
KR101583452B9 (en) 2022-05-02
PH12017550051A1 (en) 2018-01-29
CO2017006222A2 (en) 2017-09-20
AR105413A1 (en) 2017-10-04
UA116517C2 (en) 2018-03-26
WO2016122226A3 (en) 2016-09-15
MX2017007567A (en) 2017-10-19
EP3250199A4 (en) 2018-08-08
EP3250199A2 (en) 2017-12-06
KR101583452B1 (en) 2016-01-11
EA032385B1 (en) 2019-05-31
EA032385B9 (en) 2019-07-31
MY195824A (en) 2023-02-22
JP2018503672A (en) 2018-02-08
JP6419347B2 (en) 2018-11-07
BR112017013857A2 (en) 2018-02-27
TW201639559A (en) 2016-11-16
WO2016122226A2 (en) 2016-08-04
CN107205947A (en) 2017-09-26
ECSP17038599A (en) 2017-09-29
CL2017001680A1 (en) 2018-01-12

Similar Documents

Publication Publication Date Title
CL2018003681A1 (en) Boronic acid derivatives and therapeutic uses thereof
AR104984A1 (en) SELECTIVE COMPOUNDS FOR PYY AND ITS USES
ES2973279T3 (en) Uses of duloxetine·HCl medication in the preparation of a pharmaceutical composition for the treatment of cancer
EA201691988A1 (en) DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION
GT201500053A (en) PHARMACEUTICAL COMPOSITION COVERED WITH REGORAFENIB
CL2016001918A1 (en) Heteroaryl amides as protein aggregation inhibitors
PE20211069A1 (en) COMPOSITION INCLUDING 5'-METHYLSEELENOADENOSINE, SELENOADENOSYL-L-HOMOCYSTEIN AND GLUTAMYL-METHYLSELENOCYSTEINE RANGE
CL2017001483A1 (en) Fixed ratio formulation of insulin glargine / lixisenatide
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
EA201691490A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BRINZOLAMIDE
CR20150266A (en) MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB
BR112016027435A2 (en) innovative formulation of meloxicam
GT201700016A (en) [1,2,4] TRIAZOLO [4,3 -B] PIRIDAZINAS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES
EA201501164A1 (en) SOLID PHARMACEUTICAL MEDICINE FORM
PE20150167A1 (en) (R) -NIFURATEL, ITS USE FOR THE TREATMENT OF INFECTIONS AND SYNTHESIS OF (R) AND (S) -NIFURATEL
BR112014032583A2 (en) pharmaceutical form for prolonged release of active substances
CR20160529A (en) PHARMACEUTICAL COMPOSITIONS TO TREAT INFECTIOUS DISEASES
PE20171340A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES
AR101901A1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES WITH A COMBINATION OF LAQUINIMOD AND FINGOLIMOD
CL2018002848A1 (en) Liquid phosphoplatin formulations
CL2019003288A1 (en) A pharmaceutical combination for the treatment of cancer.
CO2018010142A2 (en) Mesalazine solid formula preparation process
EA202091403A1 (en) 2-OXO-1-PYRROLIDINYLIMIDAZOTHIAZOLE DERIVATIVES
ES2537905B2 (en) Use of 12-deoxiforboles to promote the proliferation of neural stem cells
CL2017003465A1 (en) Combined use of bumetanide with valproic acid or one of its pharmaceutically acceptable salts to restore cl-homeostasis and thereby allow the preparation of an effective drug in the treatment of epilepsy, and especially in the treatment of refractory epilepsy.